Company news
MBX Biosciences, Inc. news in 2024
MBX Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism
December 1, 2024
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
November 17, 2024
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
MBX Biosciences to Participate in Upcoming November Investor Conferences
October 27, 2024
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
September 29, 2024
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 15, 2024
MBX Biosciences Announces Pricing of Initial Public Offering
September 11, 2024